View Older Stories View More Recent Stories

Jan 5, 2023 07:12AM NorthSea Therapeutics Provides Clinical Update Reflecting Progress Across NASH And Metabolic Disorders Programmes
Dec 21, 2022 07:10AM NorthSea Therapeutics Appoints Morris J. Birnbaum to the Board
Dec 15, 2022 05:02PM Form SC 13D/A Ventyx Biosciences, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Dec 6, 2022 08:06AM 4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Dec 6, 2022 07:00AM Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Nov 21, 2022 08:30AM FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Nov 14, 2022 04:39PM Form 13F-HR venBio Partners LLC For: Sep 30
Sep 26, 2022 04:25PM Form SC 13D/A Pharvaris N.V. Filed by: venBio Global Strategic Fund III, L.P.
Sep 26, 2022 04:22PM Form SC 13D/A Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Sep 26, 2022 04:19PM Form SC 13G/A CinCor Pharma, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Sep 15, 2022 05:02PM Form SC 13D/A Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund II L.P.
Sep 14, 2022 05:02PM Form SC 13D/A Ventyx Biosciences, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Sep 13, 2022 07:00AM ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases
Aug 15, 2022 05:00PM Form 13F-HR venBio Partners LLC For: Jun 30
Aug 8, 2022 08:55AM InBrace Closes New Round of $45M Financing To Accelerate Growth And Market Expansion
Jul 11, 2022 04:29PM Horizon Technology Finance Leads $45 Million Venture Loan Facility to InBrace
Jun 10, 2022 06:23PM Form 4 Ventyx Biosciences, Inc. For: Jun 09 Filed by: venBio Global Strategic Fund III, L.P.
Jun 7, 2022 04:16PM Form SC 13G/A Checkmate Pharmaceutical Filed by: venBio Global Strategic Fund II L.P.
May 27, 2022 07:22PM Form 4 Elevation Oncology, Inc. For: May 25 Filed by: venBio Global Strategic Fund III, L.P.
May 27, 2022 06:01PM Form SC 13D/A Elevation Oncology, Inc. Filed by: venBio Global Strategic Fund III, L.P.
May 17, 2022 05:12PM Form 4 Checkmate Pharmaceutical For: May 13 Filed by: venBio Global Strategic Fund II L.P.
May 16, 2022 05:54PM Form 13F-HR venBio Partners LLC For: Mar 31
May 9, 2022 06:59PM Form 4 Checkmate Pharmaceutical For: May 05 Filed by: venBio Global Strategic Fund II L.P.
May 5, 2022 04:23PM Form SC 13G/A Checkmate Pharmaceutical Filed by: venBio Global Strategic Fund II L.P.
May 4, 2022 07:31PM Form 4 Checkmate Pharmaceutical For: May 02 Filed by: venBio Global Strategic Fund II L.P.
Apr 29, 2022 05:59PM Form 4 Checkmate Pharmaceutical For: Apr 27 Filed by: venBio Global Strategic Fund II L.P.
Apr 26, 2022 06:41PM Form 4 Checkmate Pharmaceutical For: Apr 22 Filed by: venBio Global Strategic Fund II L.P.
Mar 23, 2022 01:00PM Clint Carnell Named CEO of InBrace
Mar 9, 2022 07:00AM Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
Feb 14, 2022 05:26PM Form 13F-HR venBio Partners LLC For: Dec 31
Feb 14, 2022 02:33PM Form SC 13G/A Metacrine, Inc. Filed by: venBio Global Strategic Fund, L.P.
Feb 14, 2022 02:31PM Form SC 13G/A Harmony Biosciences Hold Filed by: venBio Global Strategic Fund II L.P.
Feb 2, 2022 03:00AM NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease
Jan 20, 2022 05:00AM ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Jan 19, 2022 07:00AM Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
Jan 11, 2022 04:47PM Form SC 13G CinCor Pharma, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Dec 29, 2021 11:29AM Form D OCA venBio IV LLC
Dec 17, 2021 07:00AM NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
Nov 29, 2021 01:00PM Ablaze Pharmaceuticals Launches with $75m Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market
Nov 16, 2021 05:00AM ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
Nov 16, 2021 03:02AM Icosabutate Latest Phase 2b Interim Data Show Significant Decreases in NASH and Fibrosis Biomarkers Independent of Fibrosis Stage and Disease Severity
Nov 15, 2021 04:46PM Form 13F-HR venBio Partners LLC For: Sep 30
Nov 4, 2021 04:18PM Form SC 13D Ventyx Biosciences, Inc. Filed by: venBio Global Strategic Fund III, L.P.
Oct 27, 2021 04:10PM PPD Reports Third Quarter and Year-To-Date 2021 Results
Oct 26, 2021 04:35PM Form 4 Metacrine, Inc. For: Oct 22 Filed by: venBio Global Strategic Fund, L.P.
Oct 25, 2021 07:41PM Form 4 Ventyx Biosciences, Inc. For: Oct 25 Filed by: venBio Global Strategic Fund III, L.P.
Oct 20, 2021 06:46PM Form 3 Ventyx Biosciences, Inc. For: Oct 20 Filed by: venBio Global Strategic Fund III, L.P.
Oct 19, 2021 10:00AM HistoWiz Raises $32M Series A Financing
Oct 18, 2021 08:00AM NFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
Oct 12, 2021 08:00AM CinCor Pharma Raises $143 Million in Series B Financing
View More Recent Stories View Older Stories